Filename 2021_Spring_CMTA_Report.pdf
Filesize 4.02 MB
Version 1
Date added April 22, 2021
Downloaded 3640 times
Category The CMTA Report

The Special Research Edition of the Spring 2021 CMTA Report is available now and full of information for you. Inside, we bring you coverage of every aspect of CMTA-STAR from cross-type initiatives to our demyelinating and axonal research portfolios to clinical trial readiness—and so much more. This special report has everything about CMTA-STAR, all in one issue!

  • A Message from CEO Amy Gray
  • Building and Paying for a STAR
  • Cross-Type Initiatives
  • INC Explained
  • Marking 38 Years of Growth
  • STAR’s Portfolio for Demyelinating CMTs – 1A, 1B, 1X [and Some 4s]
  • A Look at 1A STAR Biotech Alliance Partners
  • Developing and Characterizing New Mouse Models of CMT1X
  • STAR 1A Timeline: CMTA Roadmap to Success
  • Pharnext Announces Phase 3 Clinical Trials for 1A
  • Clinical Trials – The Road to Drug Approval
  • The Challenge of Rare Diseases
  • Why We Give: We Believe in the CMTA
  • Filling the Pipeline: The CMTA-STAR Funding Process
  • STAR’s Portfolio for Axonal CMTs – Type 2 [and Some 4s]
  • The CMTA’s Type 2 Gene Discovery Initiatives
  • The CMT2A Gene Replacement Therapy Initiative
  • CMT2A Researchers on the Way to Being Trial Ready
  • Wondering How You Can Get Involved?